The state-of-play and future of antibody therapeutics

Ecker, 2015, The therapeutic monoclonal antibody market, MAbs, 7, 9, 10.4161/19420862.2015.989042 Kontermann, 2015, Bispecific antibodies, Drug Discov. Today, 20, 838, 10.1016/j.drudis.2015.02.008 Drake, 2015, An emerging playbook for antibody-drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety, Curr. Opin. Chem. Biol., 28, 174, 10.1016/j.cbpa.2015.08.005 Kohler, 1975, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256, 495, 10.1038/256495a0 Kohler, 1976, Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion, Eur. J. Immunol., 6, 511, 10.1002/eji.1830060713 Li, 2010, New perspective for phage display as an efficient and versatile technology of functional proteomics, Appl. Microbiol. Biotechnol., 85, 909, 10.1007/s00253-009-2277-0 Jones, 1986, Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, 321, 522, 10.1038/321522a0 Riechmann, 1988, Reshaping human antibodies for therapy, Nature, 332, 323, 10.1038/332323a0 Lonberg, 2005, Human antibodies from transgenic animals, Nat. Biotechnol., 23, 1117, 10.1038/nbt1135 Scott, 2007, Mice with a human touch, Nat. Biotechnol., 25, 1075, 10.1038/nbt1007-1075 Jakobovits, 2007, From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice, Nat. Biotechnol., 25, 1134, 10.1038/nbt1337 Huse, 1989, Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda, Science, 246, 1275, 10.1126/science.2531466 McCafferty, 1990, Phage antibodies: filamentous phage displaying antibody variable domains, Nature, 348, 552, 10.1038/348552a0 Barbas, 1991, Assembly of combinatorial antibody libraries on phage surfaces: the gene III site, Proc. Natl. Acad. Sci., 88, 7978, 10.1073/pnas.88.18.7978 Schofield, 2007, Application of phage display to high throughput antibody generation and characterization, Genome Biol., 8, 10.1186/gb-2007-8-11-r254 Marks, 1991, By-passing immunization. Human antibodies from V-gene libraries displayed on phage, J. Mol. Biol., 222, 581, 10.1016/0022-2836(91)90498-U Barbas, 1992, Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem, Proc. Natl. Acad. Sci., 89, 4457, 10.1073/pnas.89.10.4457 Hoogenboom, 1992, By-passing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro, J. Mol. Biol., 227, 381, 10.1016/0022-2836(92)90894-P Hoogenboom, 1991, Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains, Nucleic Acids Res., 19, 4133, 10.1093/nar/19.15.4133 Davies, 1995, An antibody variable heavy domain with a lox-Cre site integrated into its coding region: bacterial recombination within a single polypeptide chain, FEBS Lett., 377, 92, 10.1016/0014-5793(95)01313-X Harmsen, 2007, Properties, production, and applications of camelid single-domain antibody fragments, Appl. Microbiol. Biotechnol., 77, 13, 10.1007/s00253-007-1142-2 Nuttall, 2003, Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70, Eur. J. Biochem., 270, 3543, 10.1046/j.1432-1033.2003.03737.x Nakano, 2009, Effective screening method of agonistic diabodies based on autocrine growth, J. Immunol. Methods, 347, 31, 10.1016/j.jim.2009.05.012 Mazor, 2007, Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli, Nat. Biotechnol., 25, 563, 10.1038/nbt1296 Jespers, 1994, Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen, Biotechnology (N Y), 12, 899 Nixon, 2014, Drugs derived from phage display: from candidate identification to clinical practice, MAbs, 6, 73, 10.4161/mabs.27240 Daugherty, 1998, Antibody affinity maturation using bacterial surface display, Protein Eng., 11, 825, 10.1093/protein/11.9.825 Feldhaus, 2003, Flow-cytometric isolation of human antibodies from a non immune Sacchromyces cerevisiae surface display library, Nat. Biotechnol., 21, 163, 10.1038/nbt785 Mottershead, 2000, Baculoviral display of functional scFv and synthetic IgG-binding domains, Biochem. Biophys. Res. Commun., 275, 84, 10.1006/bbrc.2000.3264 Hanes, 2000, Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display, Nat. Biotechnol., 18, 1287, 10.1038/82407 Georgiou, 2014, The promise and challenge of high-throughput sequencing of the antibody repertoire, Nat. Biotechnol., 32, 158, 10.1038/nbt.2782 Ravn, 2013, Deep sequencing of phage display libraries to support antibody discovery, Methods, 60, 99, 10.1016/j.ymeth.2013.03.001 Mathonet, 2013, The application of next generation sequencing to the understanding of antibody repertoires, Front. Immunol., 4, 10.3389/fimmu.2013.00265 Cheung, 2012, A proteomics approach for the identification and cloning of monoclonal antibodies from serum, Nat. Biotechnol., 30, 447, 10.1038/nbt.2167 Reddy, 2010, Monoclonal antibodies isolated without screening by analyzing the variable-gene repertoire of plasma cells, Nat. Biotechnol., 28, 965, 10.1038/nbt.1673 Ravn, 2010, By-passing in vitro screening–next generation sequencing technologies applied to antibody display and in silico candidate selection, Nucleic Acids Res., 38, 10.1093/nar/gkq789 DeKosky, 2013, High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire, Nat. Biotechnol., 31, 166, 10.1038/nbt.2492 Saggy, 2012, Antibody isolation from immunized animals: comparison of phage display and antibody discovery via V gene repertoire mining, Protein Eng. Des. Sel., 25, 539, 10.1093/protein/gzs060 Lehmann-Horn, 2013, Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges, Ther. Adv. Neurol. Disord., 6, 161, 10.1177/1756285612474333 Vazquez, 2012, Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data, Front. Oncol., 2, 150, 10.3389/fonc.2012.00150 Garrone, 1996, Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor, Mol. Immunol., 33, 649, 10.1016/0161-5890(96)00017-X Hong, 2014, MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study, Lancet Oncol., 15, 656, 10.1016/S1470-2045(14)70155-X Kim, 2014, Biosimilars: challenges and path forward, Biotechnol. Bioprocess Eng., 19, 755, 10.1007/s12257-013-0756-8 Berghout, 2011, Clinical programs in the development of similar biotherapeutic products: rationale and general principles, Biologicals, 39, 293, 10.1016/j.biologicals.2011.06.024 Kudrin, 2015, Case studies on clinical evaluation of biosimilar monoclonal antibody: scientific considerations for regulatory approval, Biologicals, 43, 1, 10.1016/j.biologicals.2014.11.002 WHO, 2009, Guidelines on evaluation of similar biotherapeutic products (SBPs) European Medicines Agency, 2008 Committee for Medicinal Products for Human Use, 2012 Committee for Medicinal Products for Human Use, 2012 Committee for Medicinal Products for Human Use, 2014 Committee for Medicinal Products for Human Use, 2014 Committee for Medicinal Products for Human Use, 2014 Food and Drug Administration, 2015 Food and Drug Administration, 2015 Food and Drug Administration, Guidance for Industry, 2014 Thimmaraju, 2015, Legislations on biosimilar interchangeability in the US and EU – developments far from visibility, Generics Biosimilars Initiative Smits, 2016, Clinical outcomes following a switch from remicade to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study, J. Crohns Colitis, 10, 1287, 10.1093/ecco-jcc/jjw087 Brown, 2016, Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health, Biologicals, 44, 257, 10.1016/j.biologicals.2016.03.006 de Labry, 2013, Biosimilars in the European market, Generics Biosimilars Initiative J. (GaBI J.), 2, 30, 10.5639/gabij.2013.0201.012 Blackstone, 2013, The economics of biosimilars, Am. Health Drug Benefits, 6, 469 Chames, 2009, Therapeutic antibodies: successes, limitations and hopes for the future, Br. J. Pharmacol., 157, 220, 10.1111/j.1476-5381.2009.00190.x Niwa, 2015, The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology, J. Pharm. Sci., 104, 930, 10.1002/jps.24316 Evans, 2014, From the analyst's couch: next-generation antibodies, Nat. Rev. Drug Discov., 13, 413, 10.1038/nrd4255 Shpilberg, 2013, Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase, Br. J. Cancer, 109, 1556, 10.1038/bjc.2013.371 Derer, 2012, Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function, Methods Mol. Biol., 907, 519, 10.1007/978-1-61779-974-7_30 Beck, 2012, Marketing approval of mogamulizumab: a triumph for glyco-engineering, MAbs, 4, 419, 10.4161/mabs.20996 Sachdeva, 2015, Obinutuzumab: a FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia, Int. J. Appl. Basic Med. Res., 5, 54, 10.4103/2229-516X.149245 Ratner, 2014, Genentech's glyco-engineered antibody to succeed Rituxan, Nat. Biotechnol., 32 Subramaniam, 2012, Mogamulizumab: first global approval, Drugs, 72, 1293, 10.2165/11631090-000000000-00000 Kakkar, 2015, Obinutuzumab for chronic lymphocytic leukemia: promise of the first treatment approved with breakthrough therapy designation, J. Oncol. Pharm. Pract., 21, 358, 10.1177/1078155214534868 Liu, 2015, Afucosylated antibodies increase activation of FcgammaRIIIa-dependent signaling components to intensify processes promoting ADCC, Cancer Immunol. Res., 3, 173, 10.1158/2326-6066.CIR-14-0125 Mizushima, 2011, Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans, Genes Cells, 16, 1071, 10.1111/j.1365-2443.2011.01552.x Preithner, 2006, High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G, Mol. Immunol., 43, 1183, 10.1016/j.molimm.2005.07.010 Zhang, 2011, Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study, MAbs, 3, 289, 10.4161/mabs.3.3.15532 Shields, 2001, High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R, J. Biol. Chem., 276, 6591, 10.1074/jbc.M009483200 Lazar, 2006, Engineered antibody Fc variants with enhanced effector function, Proc. Natl. Acad. Sci., 103, 4005, 10.1073/pnas.0508123103 Stavenhagen, 2007, Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors, Cancer Res., 67, 8882, 10.1158/0008-5472.CAN-07-0696 Jung, 2010, Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells, Proc. Natl. Acad. Sci., 107, 604, 10.1073/pnas.0908590107 Sazinsky, 2008, Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors, Proc. Natl. Acad. Sci., 105, 20167, 10.1073/pnas.0809257105 Borrok, 2012, Revisiting the role of glycosylation in the structure of human IgG Fc, ACS Chem. Biol., 7, 1596, 10.1021/cb300130k Stewart, 2011, A variant human IgG1-Fc mediates improved ADCC, Protein Eng. Des. Sel., 24, 671, 10.1093/protein/gzr015 Kayser, 2011, Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies, Biotechnol. J., 6, 38, 10.1002/biot.201000091 Mimura, 2000, The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms, Mol. Immunol., 37, 697, 10.1016/S0161-5890(00)00105-X Zaro, 2015, Mylotarg: revisiting its clinical potential post-withdrawal, 179 Burrows, 1993, Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature, Proc. Natl. Acad. Sci., 90, 8996, 10.1073/pnas.90.19.8996 Palumbo, 2011, A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels, Br. J. Cancer, 104, 1106, 10.1038/bjc.2011.78 Visintin, 2015, Novel anti-TM4SF1 antibody-drug conjugates with activity against tumor cells and tumor vasculature, Mol. Cancer Ther., 14, 1868, 10.1158/1535-7163.MCT-15-0188 Ostermann, 2008, Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts, Clin. Cancer Res., 14, 4584, 10.1158/1078-0432.CCR-07-5211 Quail, 2013, Microenvironmental regulation of tumor progression and metastasis, Nat. Med., 19, 1423, 10.1038/nm.3394 Pettit, 1987, The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10, J. Am. Chem. Soc., 109, 6883, 10.1021/ja00256a070 Maiese, 1989, Calicheamicins, a novel family of antitumor antibiotics: taxonomy, fermentation and biological properties, J. Antibiot., 42, 558, 10.7164/antibiotics.42.558 Cassady, 2004, Recent developments in the maytansinoid antitumor agents, Chem. Pharm. Bull., 52, 1, 10.1248/cpb.52.1 Chari, 2008, Targeted cancer therapy: conferring specificity to cytotoxic drugs, Acc. Chem. Res., 41, 98, 10.1021/ar700108g Doronina, 2006, Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity, Bioconjug. Chem., 17, 114, 10.1021/bc0502917 Jerjian, 2016, Antibody-drug conjugates: a clinical pharmacy perspective on an emerging cancer therapy, Pharmacotherapy, 36, 99, 10.1002/phar.1687 Elgersma, 2015, Design, synthesis, and evaluation of linker-duocarmycin payloads: toward selection of HER2-targeting antibody-drug conjugate SYD985, Mol. Pharm., 12, 1813, 10.1021/mp500781a Hartley, 2011, The development of pyrrolobenzodiazepines as antitumour agents, Expert Opin. Investig. Drugs, 20, 733, 10.1517/13543784.2011.573477 Koblinski, 2000, Unraveling the role of proteases in cancer, Clin. Chim. Acta, 291, 113, 10.1016/S0009-8981(99)00224-7 Doronina, 2003, Development of potent monoclonal antibody auristatin conjugates for cancer therapy, Nat. Biotechnol., 21, 778, 10.1038/nbt832 Vaklavas, 2012, Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma, Ther. Adv. Hematol., 3, 209, 10.1177/2040620712443076 Bendell, 2014, Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer, J. Clin. Oncol., 32, 3619, 10.1200/JCO.2013.52.5683 Erickson, 2006, Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing, Cancer Res., 66, 4426, 10.1158/0008-5472.CAN-05-4489 Alley, 2007, Effects of linker chemistry on tumor targeting by anti-CD70 antibody-drug conjugates, Cancer Res., 67, 916 Girish, 2012, Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer, Cancer Chemother. Pharmacol., 69, 1229, 10.1007/s00280-011-1817-3 Polson, 2009, Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection, Cancer Res., 69, 2358, 10.1158/0008-5472.CAN-08-2250 Erickson, 2012, The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates, Mol. Cancer Ther., 11, 1133, 10.1158/1535-7163.MCT-11-0727 Lyon, 2012, Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues, Methods Enzymol., 502, 123, 10.1016/B978-0-12-416039-2.00006-9 Brun, 2013, Protocols for lysine conjugation, Methods Mol. Biol., 1045, 173, 10.1007/978-1-62703-541-5_10 Behrens, 2015, Antibody-drug conjugates (ADCs) derived from interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over conventional heterogeneous ADCs, Mol. Pharm., 12, 3986, 10.1021/acs.molpharmaceut.5b00432 Junutula, 2008, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index, Nat. Biotechnol., 26, 925, 10.1038/nbt.1480 Axup, 2012, Synthesis of site-specific antibody-drug conjugates using unnatural amino acids, Proc. Natl. Acad. Sci., 109, 16101, 10.1073/pnas.1211023109 Zimmerman, 2014, Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system, Bioconjug. Chem., 25, 351, 10.1021/bc400490z Sochaj, 2015, Current methods for the synthesis of homogeneous antibody-drug conjugates, Biotechnol. Adv., 33, 775, 10.1016/j.biotechadv.2015.05.001 van Geel, 2015, Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody-drug conjugates, Bioconjug. Chem., 26, 2233, 10.1021/acs.bioconjchem.5b00224 Nisonoff, 1961, Recombination of a mixture of univalent antibody fragments of different specificity, Arch. Biochem. Biophys., 93, 460, 10.1016/0003-9861(61)90296-X Staerz, 1986, Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity, Proc. Natl. Acad. Sci., 83, 1453, 10.1073/pnas.83.5.1453 Gunasekaran, 2010, Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG, J. Biol. Chem., 285, 19637, 10.1074/jbc.M110.117382 Von Kreudenstein, 2013, Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design, MAbs, 5, 646, 10.4161/mabs.25632 Lewis, 2014, Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface, Nat. Biotechnol., 32, 191, 10.1038/nbt.2797 Ridgway, 1996, ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization, Protein Eng. Des. Sel., 9, 617, 10.1093/protein/9.7.617 Schaefer, 2011, Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies, Proc. Natl. Acad. Sci., 108, 11187, 10.1073/pnas.1019002108 Rossi, 2006, Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc. Natl. Acad. Sci., 103, 6841, 10.1073/pnas.0600982103 Rossi, 2012, The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures, Bioconjug. Chem., 23, 309, 10.1021/bc2004999 Davis, 2010, SEED bodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies, Protein Eng. Des. Sel., 23, 195, 10.1093/protein/gzp094 Zeidler, 2000, The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells, Br. J. Cancer, 83, 261, 10.1054/bjoc.2000.1237 Ott, 2012, Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites, Int. J. Cancer, 130, 2195, 10.1002/ijc.26258 Wolf, 2005, BiTEs: bispecific antibody constructs with unique anti-tumor activity, Drug Discov. Today, 10, 1237, 10.1016/S1359-6446(05)03554-3 Baeuerle, 2009, BiTE: teaching antibodies to engage T-cells for cancer therapy, Curr. Opin. Mol. Ther., 11, 22 Newman, 2016, A review of blinatumomab, a novel immunotherapy, J. Oncol. Pharm. Pract., 22, 639, 10.1177/1078155215618770 Topp, 2015, Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study, Lancet Oncol., 16, 57, 10.1016/S1470-2045(14)71170-2 Johnson, 2010, Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion, J. Mol. Biol., 399, 436, 10.1016/j.jmb.2010.04.001 Moore, 2011, Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma, Blood, 117, 4542, 10.1182/blood-2010-09-306449 Kipriyanov, 1999, Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics, J. Mol. Biol., 293, 41, 10.1006/jmbi.1999.3156 McAleese, 2012, RECRUIT-TandAbs: harnessing the immune system to kill cancer cells, Future Oncol., 8, 687, 10.2217/fon.12.54 Liddy, 2012, Monoclonal TCR-redirected tumor cell killing, Nat. Med., 18, 980, 10.1038/nm.2764 Schaefer, 2011, A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies, Cancer Cell, 20, 472, 10.1016/j.ccr.2011.09.003 Wu, 2007, Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin, Nat. Biotechnol., 25, 1290, 10.1038/nbt1345 Conrath, 2001, Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae, Antimicrob. Agents Chemother., 45, 2807, 10.1128/AAC.45.10.2807-2812.2001 Jones, 2010, 60 Chartrain, 2008, Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies, Curr. Pharm. Biotechnol., 9, 447, 10.2174/138920108786786367 Robinson, 2015, Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria, Nat. Commun., 6, 8072, 10.1038/ncomms9072 Jung, 2013, Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcgammaRIIa affinity and selectivity, ACS Chem. Biol., 8, 368, 10.1021/cb300455f Li, 2006, Optimization of humanized IgGs in glycoengineered Pichia pastoris, Nat. Biotechnol., 24, 210, 10.1038/nbt1178 Potgieter, 2010, Antibody expression kinetics in glycoengineered Pichia pastoris, Biotechnol. Bioeng., 106, 918, 10.1002/bit.22756 Ye, 2011, Optimization of a glycoengineered Pichia pastoris cultivation process for commercial antibody production, Biotechnol. Prog., 27, 1744, 10.1002/btpr.695 Ma, 1994, Assembly of monoclonal antibodies with IgG1 and IgA heavy chain domains in transgenic tobacco plants, Eur. J. Immunol., 24, 131, 10.1002/eji.1830240120 De Muynck, 2010, Production of antibodies in plants: status after twenty years, Plant Biotechnol. J., 8, 529, 10.1111/j.1467-7652.2009.00494.x Moussavou, 2015, Production of monoclonal antibodies in plants for cancer immunotherapy, Biomed. Res. Int., 2015, 306164, 10.1155/2015/306164 Grohs, 2010, Plant-produced trastuzumab inhibits the growth of HER2 positive cancer cells, J. Agric. Food Chem., 58, 10056, 10.1021/jf102284f Bandaranayake, 2014, Recent advances in mammalian protein production, FEBS Lett., 588, 253, 10.1016/j.febslet.2013.11.035 Browne, 2007, Selection methods for high-producing mammalian cell lines, Trends Biotechnol., 25, 425, 10.1016/j.tibtech.2007.07.002 Shi, 2011, A high-throughput automated platform for the development of manufacturing cell lines for protein therapeutics, J. Vis. Exp., 55 Chu, 2001, Industrial choices for protein production by large-scale cell culture, Curr. Opin. Biotechnol., 12, 180, 10.1016/S0958-1669(00)00197-X Liu, 2010, Recovery and purification process development for monoclonal antibody production, MAbs, 2, 480, 10.4161/mabs.2.5.12645 Birch, 2006, Antibody production, Adv. Drug Deliv. Rev., 58, 671, 10.1016/j.addr.2005.12.006 Fahrner, 2001, Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes, Biotechnol. Genet. Eng. Rev., 18, 301, 10.1080/02648725.2001.10648017 Schwart, 2001, Comparison of hydrophobic charge induction chromatography with affinity chromatography on protein A for harvest and purification of antibodies, J. Chromatogr. A, 908, 251, 10.1016/S0021-9673(00)01013-X van Reis, 1997, High performance tangential flow filtration, Biotechnol. Bioeng., 56, 71, 10.1002/(SICI)1097-0290(19971005)56:1<71::AID-BIT8>3.0.CO;2-S Lebreton, 2008, Application of high-performance tangential flow filtration (HPTFF) to the purification of a human pharmaceutical antibody fragment expressed in Escherichia coli, Biotechnol. Bioeng., 100, 964, 10.1002/bit.21842 Arakawa, 2010, MEP HyperCel chromatography II: binding, washing and elution, Protein Expr. Purif., 71, 168, 10.1016/j.pep.2009.11.004 Manzke, 1997, Single-step purification of bispecific monoclonal antibodies for immunotherapeutic use by hydrophobic interaction chromatography, J. Immunol. Methods, 208, 65, 10.1016/S0022-1759(97)00129-4 Nagorsen, 2012, Blinatumomab: a historical perspective, Pharmacol. Ther., 136, 334, 10.1016/j.pharmthera.2012.07.013 Ducry, 2012, Challenges in the development and manufacturing of antibody-drug conjugates, Methods Mol. Biol., 899, 489, 10.1007/978-1-61779-921-1_29 Rader, 2014 Scanlan, 2014, Challenges and Strategies for the Downstream Processing of BiSpecific Antibodies (BsAbs) Joubert, 2012, Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses, J. Biol. Chem., 287, 25266, 10.1074/jbc.M111.330902 Hermeling, 2004, Structure-immunogenicity relationships of therapeutic proteins, Pharm. Res., 21, 897, 10.1023/B:PHAM.0000029275.41323.a6 Rehder, 2008, Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity, Biochemistry, 47, 2518, 10.1021/bi7018223 Daugherty, 2006, Formulation and delivery issues for monoclonal antibody therapeutics, Adv. Drug Deliv. Rev., 58, 686, 10.1016/j.addr.2006.03.011 Yan, 2016, Isomerization and oxidation in the complementarity-determining regions of a monoclonal antibody: a study of the modification–structure–function correlations by hydrogen–deuterium exchange mass spectrometry, Anal. Chem., 88, 2041, 10.1021/acs.analchem.5b02800 Moorthy, 2015, Structure of monoclonal antibodies, 81 Chennamsetty, 2009, Design of therapeutic proteins with enhanced stability, Proc. Natl. Acad. Sci., 106, 11937, 10.1073/pnas.0904191106 Chennamsetty, 2010, Prediction of aggregation prone regions of therapeutic proteins, J. Phys. Chem. B, 114, 6614, 10.1021/jp911706q Courtois, 2015, Rational design of biobetters with enhanced stability, J. Pharm. Sci., 104, 2433, 10.1002/jps.24520 Ahmadi, 2015, Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics, Pharm. Res., 32, 1383, 10.1007/s11095-014-1541-x Bessa, 2015, The immunogenicity of antibody aggregates in a novel transgenic mouse model, Pharm. Res., 32, 2344, 10.1007/s11095-015-1627-0 Manning, 2010, Stability of protein pharmaceuticals: an update, Pharm. Res., 27, 544, 10.1007/s11095-009-0045-6 Sahin, 2010, Comparative effects of pH and ionic strength on protein–protein interactions, unfolding, and aggregation for IgG1 antibodies, J. Pharm. Sci., 99, 4830, 10.1002/jps.22198 Arosio, 2013, Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates, Pharm. Res., 30, 641, 10.1007/s11095-012-0885-3 Telikepalli, 2014, Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions, J. Pharm. Sci., 103, 796, 10.1002/jps.23839 Depreter, 2013, Inhaled proteins: challenges and perspectives, Int. J. Pharm., 447, 251, 10.1016/j.ijpharm.2013.02.031 Kayser, 2011, Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation, J. Pharm. Sci., 100, 2526, 10.1002/jps.22493 Kim, 2013, Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration, Biophys. Chem., 172, 26, 10.1016/j.bpc.2012.12.004 Wu, 2014, Competing aggregation pathways for monoclonal antibodies, FEBS Lett., 588, 936, 10.1016/j.febslet.2014.01.051 Mehta, 2014, Partial unfolding of a monoclonal antibody: role of a single domain in driving protein aggregation, Biochemistry, 53, 3367, 10.1021/bi5002163 Razinkov, 2015, Accelerated formulation development of monoclonal antibodies (mAbs) and mAb-based modalities: review of methods and tools, J. Biomol. Screen., 20, 468, 10.1177/1087057114565593 Liu, 2006, Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature, J. Chromatogr. B, 837, 35, 10.1016/j.jchromb.2006.03.053 Vlasak, 2011, Fragmentation of monoclonal antibodies, MAbs, 3, 253, 10.4161/mabs.3.3.15608 Harris, 2001, Identification of multiple sources of charge heterogeneity in a recombinant antibody, J. Chromatogr. B Biomed. Sci. Appl., 752, 233, 10.1016/S0378-4347(00)00548-X Liu, 2008, Glutamine deamidation of a recombinant monoclonal antibody, Rapid Commun. Mass Spectrom., 22, 4081, 10.1002/rcm.3831 Zhang, 2014, Characterization of asparagine 330 deamidation in an Fc-fragment of IgG1 using cation exchange chromatography and peptide mapping, J. Chromatogr. B, 965, 65, 10.1016/j.jchromb.2014.06.018 Pace, 2013, Asparagine deamidation dependence on buffer type, pH, and temperature, J. Pharm. Sci., 102, 1712, 10.1002/jps.23529 Yi, 2013, Isomerization of Asp–Asp motif in model peptides and a monoclonal antibody fab fragment, J. Pharm. Sci., 102, 947, 10.1002/jps.23423 Timm, 2010, Identification and characterization of oxidation and deamidation sites in monoclonal rat/mouse hybrid antibodies, J. Chromatogr. B, 878, 777, 10.1016/j.jchromb.2010.01.036 Huang, 2005, In vivo deamidation characterization of monoclonal antibody by LC/MS/MS, Anal. Chem., 77, 1432, 10.1021/ac0494174 Sreedhara, 2016, Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development, Eur. J. Pharm. Biopharm., 100, 38, 10.1016/j.ejpb.2015.12.003 Sreedhara, 2013, Role of Surface Exposed Tryptophan as Substrate Generators for the Antibody Catalyzed Water Oxidation Pathway, Mol. Pharm., 10, 278, 10.1021/mp300418r Torosantucci, 2014, Oxidation of therapeutic proteins and peptides: structural and biological consequences, Pharm. Res., 31, 541, 10.1007/s11095-013-1199-9 Wang, 2011, Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies, Mol. Immunol., 48, 860, 10.1016/j.molimm.2010.12.009 Wang, 2007, Antibody structure, instability, and formulation, J. Pharm. Sci., 96, 1, 10.1002/jps.20727 Yan, 2009, Human IgG1 hinge fragmentation as the result of H2O2-mediated radical cleavage, J. Biol. Chem., 284, 35390, 10.1074/jbc.M109.064147 Wei, 2007, Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus, Anal. Chem., 79, 2797, 10.1021/ac062311j Wilson, 2015, Rational protein design: developing next-generation biological therapeutics and nanobiotechnological tools, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 7, 330, 10.1002/wnan.1310 Cerda-Costa, 2007, Early kinetics of amyloid fibril formation reveals conformational reorganisation of initial aggregates, J. Mol. Biol., 366, 1351, 10.1016/j.jmb.2006.12.007 de Groot, 2005, Prediction of “hot spots” of aggregation in disease-linked polypeptides, BMC Struct. Biol., 5, 18, 10.1186/1472-6807-5-18 Ogmen, 2005, PRISM: protein interactions by structural matching, Nucleic Acids Res., 33, W331, 10.1093/nar/gki585 Tartaglia, 2008, The Zyggregator method for predicting protein aggregation propensities, Chem. Soc. Rev., 37, 1395, 10.1039/b706784b Trovato, 2007, The PASTA server for protein aggregation prediction, Protein Eng. Des. Sel., 10.1093/protein/gzm042 Tartaglia, 2005, Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences, Protein Sci., 14, 2723, 10.1110/ps.051471205 Wang, 2009, Potential aggregation prone regions in biotherapeutics, MAbs, 1, 254, 10.4161/mabs.1.3.8035 Angarica, 2012, Protein dynamics governed by interfaces of high polarity and low packing density, PLoS ONE, 7, 10.1371/journal.pone.0048212 Zambrano, 2015, AGGRESCAN3D (A3D): server for prediction of aggregation properties of protein structures, Nucleic Acids Res., 43, W306, 10.1093/nar/gkv359 Schweizer, 2014, Controlled release of therapeutic antibody formats, Eur. J. Pharm. Biopharm., 88, 291, 10.1016/j.ejpb.2014.08.001 Karow, 2013, Buffer capacity of biologics - from buffer salts to buffering by antibodies, Biotechnol. Prog., 29, 480, 10.1002/btpr.1682 Chang, 2005, Effect of sorbitol and residual moisture on the stability of lyophilized antibodies: Implications for the mechanism of protein stabilization in the solid state, J. Pharm. Sci., 94, 1445, 10.1002/jps.20363 Platts, 2015, Controlling protein stability: mechanisms revealed using formulations of arginine, glycine and guanidinium HCl with three globular proteins, Int. J. Pharm., 486, 131, 10.1016/j.ijpharm.2015.03.051 Ohtake, 2011, Interactions of formulation excipients with proteins in solution and in the dried state, Adv. Drug Deliv. Rev., 63, 1053, 10.1016/j.addr.2011.06.011 Yang, 2003, Crystalline monoclonal antibodies for subcutaneous delivery, Proc. Natl. Acad. Sci., 100, 6934, 10.1073/pnas.1131899100 Schweizer, 2013, Protein-polyanion interactions for the controlled release of monoclonal antibodies, Biomacromolecules, 14, 75, 10.1021/bm301352x Grainger, 2004, Controlled-release and local delivery of therapeutic antibodies, Expert. Opin. Biol. Ther., 4, 1029, 10.1517/14712598.4.7.1029 Shimizu, 1993, Encapsulation of chicken egg yolk immunoglobulin G (IgY) by liposomes, Biosci. Biotechnol. Biochem., 57, 1445, 10.1271/bbb.57.1445 Li, 2007, Chitosan-alginate microcapsules for oral delivery of egg yolk immunoglobulin (IgY), J. Agric. Food Chem., 55, 2911, 10.1021/jf062900q Yun, 2013, Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery, Adv. Drug Deliv. Rev., 65, 822, 10.1016/j.addr.2012.10.007 Streit, 2006, Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds, Int. Wound J., 3, 171, 10.1111/j.1742-481X.2006.00233.x Smola, 2008, Nanocarriers as pulmonary drug delivery systems to treat and to diagnose respiratory and non respiratory diseases, Int. J. Nanomedicine, 3, 1 Koussoroplis, 2014, PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract, J. Control. Release, 187, 91, 10.1016/j.jconrel.2014.05.021 Dellamary, 2004, Rational design of solid aerosols for immunoglobulin delivery by modulation of aerodynamic and release characteristics, J. Control. Release, 95, 489, 10.1016/j.jconrel.2003.12.013 Bot, 2000, Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract, Pharm. Res., 17, 275, 10.1023/A:1007544804864 El-Sherbiny, 2015, Inhaled nano- and microparticles for drug delivery, Glob. Cardiol. Sci. Pract., 2015, 2, 10.5339/gcsp.2015.2 Detalle, 2016, Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection, Antimicrob. Agents Chemother., 60, 6, 10.1128/AAC.01802-15